Supernus Pharmaceuticals
(NASDAQ) SUPN
Supernus Pharmaceuticals Financials at a Glance
Market Cap
$2.92B
Revenue (TTM)
$718.95M
Net Income (TTM)
$38.55M
EPS (TTM)
$-0.68
P/E Ratio
-74.10
Dividend
$0.00
Beta (Volatility)
0.63 (Low)
Dividend
$0.00
Beta (Volatility)
0.63 (Low)
Price
$49.92
Volume
6,836
Open
$50.45
Price
$49.92
Volume
6,836
Open
$50.45
Previous Close
$50.68
Daily Range
$49.65 - $50.76
52-Week Range
$29.16 - $59.68
Dividend
$0.00
Beta (Volatility)
0.63 (Low)
Price
$49.92
Volume
6,836
Open
$50.45
Previous Close
$50.68
Daily Range
$49.65 - $50.76
52-Week Range
$29.16 - $59.68
SUPN News
SUPN: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Supernus Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
778
CEO
Jack A. Khattar, MBA
Website
www.supernus.comHeadquarters
Rockville, MD 20850, US
SUPN Financials
Key Financial Metrics (TTM)
Gross Margin
86%
Operating Margin
-6%
Net Income Margin
-5%
Return on Equity
-4%
Return on Capital
-4%
Return on Assets
-3%
Earnings Yield
-1.35%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.92B
Shares Outstanding
57.58M
Volume
6.84K
Short Interest
0.00%
Avg. Volume
732.34K
Financials (TTM)
Gross Profit
$644.39M
Operating Income
$36.86M
EBITDA
$41.00M
Operating Cash Flow
$47.33M
Capital Expenditure
$1.34M
Free Cash Flow
$45.99M
Cash & ST Invst.
$308.67M
Total Debt
$40.98M
Supernus Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$211.57M
+21.5%
Gross Profit
$188.56M
+27.4%
Gross Margin
89.13%
N/A
Market Cap
$2.92B
N/A
Market Cap/Employee
$4.33M
N/A
Employees
674
N/A
Net Income
$4.11M
-126.8%
EBITDA
$90.26M
+99.6%
Quarterly Fundamentals
Net Cash
$267.69M
-36.2%
Accounts Receivable
$187.80M
+32.2%
Inventory
$82.39M
+51.7%
Long Term Debt
$30.36M
+10.9%
Short Term Debt
$10.61M
+54.0%
Return on Assets
-2.65%
N/A
Return on Invested Capital
-4.00%
N/A
Free Cash Flow
$19.43M
-56.0%
Operating Cash Flow
$19.86M
-55.3%